7.2 Part VI.2 Elements for a Public Summary
|
|
- Jeffry Nichols
- 6 years ago
- Views:
Transcription
1 7.2 Part VI.2 Elements for a Public Summary Part VI.2.1 Overview of disease epidemiology Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually progressive (getting worse) and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations (worsening) and comorbidities contribute to the overall severity in individual patients (Global Initiative for Chronic Obstructive Lung Disease, GOLD 2013). Unlike in asthma, airflow limitation is usually not fully reversible. Risk factors for developing COPD are smoking, air pollution and occupational exposure. Prevalence (number of affected people) estimates for COPD are approximately 600 million individuals worldwide. It is clear that prevalence is higher in smokers than in non-smokers, higher in men than in women, and increases with age. COPD is a leading cause of morbidity and mortality worldwide. Comorbidities frequently seen in COPD patients include cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression and lung cancer.
2 Sandoz Confidential Page Part VI.2.2 Summary of treatment benefits Therapeutic approaches for COPD have converged over the past two decades. Expert panels recommend a stepwise pharmacotherapy, depending on the level of disease control and disease stage (GOLD 2013). The first step to treat COPD is smoking cessation (nicotine replacement therapy with an appropriate support programme needs to be in place). Medical treatment includes short-acting and long-acting bronchodilators, including beta 2 -agonists and/or muscarinic antagonists, oral theophylline, inhaled and oral corticosteroids therapy and mucolytic therapy. Salbutamol Sulfate is indicated for the management of bronchospasm in patients suffering from chronic obstructive pulmonary disease who require regular treatment with both ipratropium and salbutamol. Beta 2 -agonists and anticholinergic agents are the main pharmacotherapy for patients with COPD. The combination of ipratropium and salbutamol is more effective than either of the two agents alone and the safety and efficacy profiles of the combination of ipratropium bromide and salbutamol are well established Part VI.2.3 Unknowns relating to treatment benefits Salbutamol Sulfate is not recommended in children below 12 years of age due to lack of data on safety and efficacy. Moreover there are no adequate data from the use of ipratropium bromide and salbutamol together in pregnant women (in early stages of pregnancy). Furthermore it is unknown whether ipratropium bromide is excreted into human breast milk. Salbutamol is excreted in human breast milk. There is insufficient/limited information on the excretion of Salbutamol Sulfate in human or animal breast milk.
3 Sandoz Confidential Page Part VI.2.4 Summary of safety concerns Table 7-5 Important identified risks Risk What is known Preventability Hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm, oropharyngeal oedema and anaphylaxis) Salbutamol Sulfate can cause allergic reactions. Symptoms of an allergic reaction are for example hives, difficult breathing, swelling of the face, lips, tongue or throat. Salbutamol Sulfate should not be used if a patient is allergic to salbutamol, ipratropium or atropine. Inhalation-induced bronchoconstriction/ paradoxical bronchospasm Ocular complications (acute angle glaucoma, mydriasis, blurring of vision, increased intraocular pressure, eye pain and narrow-angle glaucoma) Cardiac disorder (cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia and extrasystoles); myocardial ischemia) Hypokalaemia As with other inhalation therapy there is a risk of inhalation-induced constriction of the airways in the lungs due to the tightening of surrounding smooth muscles. If this occurs the patient will experience an immediate increase in wheezing and shortness of breath after dosing. There are rare reports of a number of ocular complications when aerosolised ipratropium bromide, either alone or in combination with a beta 2 -adrenergic agonist, has been inadvertently sprayed into the eye. Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. There is some evidence from postmarketing data and published literature of rare occurrences of myocardial ischaemia associated with beta-agonists. Symptoms of cardiac disorders can be for example chest pain or uneven heartbeats. Potentially serious hypokalaemia (low potassium) may result from beta 2 -agonist therapy.symptoms of low potassium can be confusion, extreme thirst, increased urination, leg discomfort or muscle The bronchoconstriction/ bronchospasm should be treated straightaway with an alternative presentation or different fastacting inhaled bronchodilator. Salbutamol Sulfate should be discontinued immediately, the patient should be assessed and, if necessary, alternative therapy instituted. Patients must therefore be instructed in the correct use of Salbutamol Sulfate with their nebuliser and must be warned not to allow the nebuliser solution or mist to enter the eyes. To avoid inadvertent entry of drug into the eye, it is preferable to administer the nebulised suspension using a mouthpiece rather than a face mask. Patients should be advised if they experience chest pain and or shortness of breath that they should contact their emergency services. Particular caution is advised in severe airway obstruction, as this effect may be potentiated by concomitant treatment with xanthine derivatives, diuretics and steroids. Potentially serious
4 Sandoz Confidential Page 19 Risk What is known Preventability weakness. arrhythmias may occur during concomitant administration of digoxin and Ipratropium Bromide + Salbutamol Sulfate. The interaction risk is aggravated by hypokalaemia and should be monitored regularly. Hypokalaemia can bring about increased sensitivity to arrhythmias in patients being treated with digoxin. Table 7-6 Risk Stroke Important potential risks What is known (Including reason why it is considered a potential risk) In 2012 the Pharmacovigilance Working Party was informed of the publication of an article by Wang et al. based on data from the Longitudinal Health Insurance Database of the Taiwan National Health Insurance programme for ipratropiumcontaining products. The UK MHRA proposed to address the signal of increased incidence of myocardial infarction and stroke in patients with COPD triggered by the publication and confirmed that initial analysis and prioritization by the Pharmacovigilance Risk Assessment Committee (PRAC) was needed. PRAC discussed the study by Wang et al. On the basis of the information provided in the publication, the PRAC considered that, given the methodological limitations of this study (e.g. confounders such as smoking status were not available) and the apparent lack of any biological plausibility, the interpretation of the results was challenging and no regulatory action is considered necessary at the moment. Table 7-7 Risk Pediatric use Pregnancy and Lactation Missing information What is known Salbutamol Sulfate should not be used in children below 12 years of age due to lack of data on safety and efficacy. It is not known whether salbutamol and ipratropium passes into breast milk or if it could harm a nursing baby. Patients should not breast-feed while using Salbutamol Sulfate.
5 Sandoz Confidential Page Part VI.2.5 Summary of additional risk minimization measures by safety concern All medicines have a Summary of Product Characteristics (SmPC) which provides physicians, pharmacists and other health care professionals with details on how to use the medicine, the risks and recommendations for minimising them. An abbreviated version of this in lay language is provided in the form of the package leaflet (PL). The measures in these documents are known as routine risk minimisation measures. This medicine has no additional risk minimisation measures Part VI.2.6 Planned post authorization development plan None Part VI.2.7 Summary of changes to the Risk Management Plan over time Not applicable (first submission)
IPRAVENT Respules/Respirator solution (Ipratropium bromide)
Published on: 19 Sep 2014 IPRAVENT Respules/Respirator solution (Ipratropium bromide) Composition IPRAVENT Respules Each 2 ml contains: Ipratropium Bromide BP equivalent to Ipratropium Bromide (anhydrous)
More informationSummary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate)
EMA/605453/2014 Summary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate) This is a summary of the risk management plan (RMP) for Duaklir Genuair, which
More informationSummary of the risk management plan (RMP) for Laventair (umeclidinium bromide and vilanterol)
EMA/258177/2014 Summary of the risk management plan (RMP) for Laventair (umeclidinium bromide and vilanterol) This is a summary of the risk management plan (RMP) for Laventair, which details the measures
More informationIPRAVENT Rotacaps (Ipratropium bromide)
Published on: 10 Jul 2014 IPRAVENT Rotacaps (Ipratropium bromide) Composition IPRAVENT Rotacaps Each capsule contains: Ipratropium Bromide BP, equivalent to Ipratropium Bromide (anhydrous) 40 mcg Excipient..q.s.
More informationElements for a Public Summary
VI.2 Elements for a Public Summary Fluticasone propionate / formoterol fumarate are available in pressarised metered dose inhalers (pmdi) under the brand names Flutiform, and in breath actuated inhalers
More informationASTHALIN Respirator Solution (Salbutamol sulphate)
Published on: 28 Jan 2016 ASTHALIN Respirator Solution (Salbutamol sulphate) Composition Each 1 ml contains: Salbutamol Sulphate IP equivalent to Salbutamol IP.. 5 mg Dosage Form Solution for inhalation
More informationASTHALIN Respules (Salbutamol sulphate)
Published on: 28 Jan 2016 ASTHALIN Respules (Salbutamol sulphate) Composition Each 2.5 ml respule contains: Salbutamol Sulphate IP equivalent to Salbutamol IP. 2.5 mg Normal saline solution.q.s. Dosage
More informationCOMBIVENT Metered Aerosol Boehringer
COMBIVENT Metered Aerosol Boehringer Composition 1 metered dose contains: (8r)-3*-Hydroxy-8-isopropyl-1*,5*-tropanium bromide (±)-tropate monohydrate (= ipratropium bromide monohydrate) 21 mcg equivalent
More informationSummary of the risk management plan (RMP) for DuoResp Spiromax (budesonide / formoterol)
EMA/126654/2014 Summary of the risk management plan (RMP) for DuoResp Spiromax (budesonide / formoterol) This is a summary of the risk management plan (RMP) for DuoResp Spiromax, which details the measures
More informationSummary of the risk management plan (RMP) for Budesonide/Formoterol Teva (budesonide / formoterol)
EMA/639304/2014 Summary of the risk management plan (RMP) for Budesonide/Formoterol Teva (budesonide / formoterol) This is a summary of the risk management plan (RMP) for Budesonide/Formoterol Teva, which
More informationSummary of the risk management plan (RMP) for Vylaer Spiromax (budesonide / formoterol)
EMA/675937/2014 Summary of the risk management plan (RMP) for Vylaer Spiromax (budesonide / formoterol) This is a summary of the risk management plan (RMP) for Vylaer Spiromax, which details the measures
More informationVENTOLIN RESPIRATOR SOLUTION
VENTOLIN RESPIRATOR SOLUTION Salbutamol QUALITATIVE AND QUANTITATIVE COMPOSITION VENTOLIN Respirator Solution contains 5mg salbutamol, as sulphate, per ml of solution and is supplied in 10 ml bottles.
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationSalapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.
Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic
More informationPRODUCT INFOMATION APO-IPRATROPIUM SOLUTION
PRODUCT INFOMATION APO-IPRATROPIUM SOLUTION NAME OF THE MEDICINE Ipratropium bromide. Chemical Name: (1R,3r,5S,8r)-3-[[(2RS)-3-Hydroxy-2-phenylpropanoyl]oxy]-8-methyl-8-(1- methylethyl)-8-azoniabicyclo[3.2.1]octane
More informationAsmol uni-dose Salbutamol (sulfate) PRODUCT INFORMATION
Asmol uni-dose Salbutamol (sulfate) PRODUCT INFORMATION NAME OF MEDICINE The active ingredient of Asmol uni-dose is salbutamol (as sulfate). The chemical name for salbutamol sulfate is: 1-(4-hydroxy-3-hydroxymethylphenyl)-2-(t-butylamino)ethanol
More informationDeveloped By Name Signature Date
Patient Group Direction 2156 version 2.0 Administration of Ipratropium 250mcg/ml Nebuliser Solution in Acute Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Date of
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Salbuvent 5 mg/2.5 ml Nebuliser Solution Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ampoule contains 5mg salbutamol (as sulphate).
More informationRISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.
RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion
More informationBRICANYL INJECTION. terbutaline sulfate PRODUCT INFORMATION
BRICANYL INJECTION terbutaline sulfate PRODUCT INFORMATION NAME OF THE MEDICINE Terbutaline sulfate, 2-(tert-butylamino)-1-(3,5-dihydroxyphenyl) ethanol sulfate, a sympathomimetic bronchodilator with a
More informationhydrochloride) from the mouthpiece. PART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr Inspiolto Respimat Tiotropium (as Tiotropium Bromide Monohydrate) / Olodaterol (as Olodaterol Hydrochloride) Inhalation Solution Read this carefully before you start taking
More informationComposition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate).
VENTOL Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate). Respiratory Solution Action Salbutamol is a short-acting, relatively selective beta2-adrenoceptor agonist.
More informationDUOLIN Rotacaps (Levosalbutamol sulphate + Ipratropium bromide)
Published on: 19 Sep 2014 DUOLIN Rotacaps (Levosalbutamol sulphate + Ipratropium bromide) Composition DUOLIN Rotacaps Each capsule contains: Levosalbutamol sulphate 100 mcg Ipratropium bromide.. 40 mcg
More informationRisk What is known Preventability Known hypersensitivity to macrolide antibiotic drugs or to any of its excipients.
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Clarithromycin 500 mg, powder for solution for infusion is indicated when parenteral therapy is required for treatment of severe
More informationMEDICATION GUIDE ANORO ELLIPTA
MEDICATION GUIDE ANORO ELLIPTA [a-nor oh e-lip-ta] (umeclidinium and vilanterol inhalation powder) for oral inhalation What is the most important information I should know about ANORO ELLIPTA? ANORO ELLIPTA
More informationIMPORTANT: PLEASE READ
IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr Spiriva Respimat Tiotropium Bromide Monohydrate Inhalation Solution Read this carefully before you start taking SPIRIVA RESPIMAT and each time you
More informationElements for a Public Summary Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Indication: Treatment of blood clots Blood clots in the large veins of the legs, known as deep vein thrombosis (DVT), are a common
More informationUtibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow
Utibron Neohaler (indacaterol, glycopyrrolate) New Product Slideshow Introduction Brand name: Utibron Neohaler Generic name: Indacaterol, glycopyrrolate Pharmacological class: Long-acting beta2- agonist
More informationNEW ZEALAND DATA SHEET SEREVENT Accuhaler
NEW ZEALAND DATA SHEET SEREVENT Accuhaler Salmeterol xinafoate (50 mcg per inhalation) Presentation SEREVENT Accuhaler is a moulded plastic device containing a foil strip with 60 regularly placed blisters
More informationPRODUCT INFORMATION VENTOLIN RESPIRATOR SOLUTION AND NEBULES
PRODUCT INFORMATION VENTOLIN RESPIRATOR SOLUTION AND NEBULES APPROVED NAME: Salbutamol Sulphate BP PHYSICAL AND CHEMICAL CHARACTERISTICS: Salbutamol sulphate is a white or almost white odourless powder.
More informationChronic obstructive pulmonary disease (COPD) is a progressive,
INFORMATION for the PHARMACIST This article was sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. Improving Lung Function (FEV 1 ) in COPD Through Appropriate Counseling on Use of Inhaled Medications
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Summary of Product Characteristics Combivent UDVs 500 micrograms/2.5mg per 2.5ml Nebuliser Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2.5ml single dose unit
More informationPRODUCT INFORMATION VENTOLIN DISKS
PRODUCT INFORMATION VENTOLIN DISKS APPROVED NAME: Salbutamol sulphate B.P. PHYSICAL AND CHEMICAL CHARACTERISTICS: Salbutamol sulphate is a white or almost white odourless powder. It is soluble in 4 parts
More informationPRODUCT INFORMATION. 1-(4-hydroxy-3-hydroxymethylphenyl)-2-(t-butylamino)ethanol Sulphate.
PRODUCT INFORMATION VENTOLIN RESPIRATOR SOLUTION AND NEBULES NAME OF THE MEDICINE: Salbutamol Sulphate BP Chemical Name: 1-(4-hydroxy-3-hydroxymethylphenyl)-2-(t-butylamino)ethanol Sulphate. Structure:
More informationSEROBID Inhaler (Salmeterol xinafoate)
Published on: 10 Jul 2014 SEROBID Inhaler (Salmeterol xinafoate) Composition Each actuation delivers: Salmeterol (as Salmeterol Xinafoate IP) 25 mcg Suspended in propellant HFA 134a.....q.s. Dosage Form
More informationPRODUCT INFORMATION. IPRAVENT Inhalation Solution Unit Dose NAME OF THE MEDICINE DESCRIPTION. Ipratropium Bromide BP
PRODUCT INFORMATION IPRAVENT Inhalation Solution Unit Dose NAME OF THE MEDICINE Ipratropium Bromide BP Ipratropium bromide is a quaternary isopropyl derivative of atropine. Its chemical name is (1R, 3r,
More informationChemical name: di[(rs)-2-(1,1-dimethyl)ethylamino-1-[4-hydroxy-3- (hydroxymethyl)phenyl]ethanol] sulphate
Product Information Page 1 PRODUCT INFORMATION SALBUTAMOL SANDOZ 2.5MG/2.5ML, 5MG/2.5ML INHALATION AMPOULES NAME OF THE MEDICINE Generic name: Salbutamol sulphate BP Chemical name: di[(rs)-2-(1,1-dimethyl)ethylamino-1-[4-hydroxy-3-
More informationPRODUCT INFORMATION. IPRAVENT Inhalation Solution Multi Dose NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. Ipratropium Bromide BP
PRODUCT INFORMATION IPRAVENT Inhalation Solution Multi Dose NAME OF THE MEDICINE Ipratropium Bromide BP Ipratropium bromide is a quaternary isopropyl derivative of atropine. Its chemical name is (1R, 3r,
More informationGenRx SALBUTAMOL INHALATION AMPOULE
GenRx SALBUTAMOL INHALATION AMPOULE NAME OF THE MEDICINE Salbutamol sulfate. Chemical Name: di[(rs)-2-(1,1-dimethyl)ethylamino-1-[4-hydroxy-3- (hydroxymethyl)phenyl]ethanol] sulfate. Structural Formula:
More informationPatient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Epidemiology of the disease Incidence and prevalence Increased pressure in the eye occurs in more than 100 million people, and
More informationPregabalin Aristo Version: RMP-Pregabalin0
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Epilepsy Epilepsy is a long-term condition affecting the brain and is characterised by recurring seizures (or fits). It is one
More informationNew Zealand Datasheet
New Zealand Datasheet 1 PRODUCT NAME Asthalin 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Salbultamol respiratory solution 3 PHARMACEUTICAL FORM Asthalin is a plastic ampoule presentation containing a sterile,
More informationPRODUCT INFORMATION VENTOLIN ROTACAPS. The chemical name of salbutamol sulfate is 1-(4-hydroxy-3-hydroxymethylphenyl)-2-(tertbutylamino)ethanol
PRODUCT INFORMATION VENTOLIN ROTACAPS NAME OF THE MEDICINE: Ventolin Rotacaps Ventolin Rotacaps contain salbutamol (as sulfate) B.P. The chemical name of salbutamol sulfate is 1-(4-hydroxy-3-hydroxymethylphenyl)-2-(tertbutylamino)ethanol
More informationPATIENT INFORMATION INCRUSE ELLIPTA
PATIENT INFORMATION INCRUSE ELLIPTA [IN-cruise e-lip-ta] (umeclidinium inhalation powder) for oral inhalation What is INCRUSE ELLIPTA? INCRUSE ELLIPTA is an anticholinergic medicine. Anticholinergic medicines
More informationSummary of risk management plan for Ulunar Breezhaler (Indacaterol/glycopyrronium)
Part VI: Summary of the risk management plan Summary of risk management plan for Ulunar Breezhaler (Indacaterol/glycopyrronium) This is a summary of the RMP for Ulunar Breezhaler. The RMP details important
More informationNocturnal polyuria has been linked to abnormalities of the daily rhythm of (circadian rhythmic) release of naturally occurring antidiuretic hormone.
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Bedwetting Bedwetting (also called primary nocturnal enuresis) is probably the most common developmental problem in children,
More informationDUOLIN Respules (Levosalbutamol sulphate + Ipratropium bromide)
Published on: 10 Jul 2014 DUOLIN Respules (Levosalbutamol sulphate + Ipratropium bromide) Composition DUOLIN Respules Each 2.5 ml unit-dose vial contains: Levosalbutamol sulphate.1.25 mg Ipratropium bromide
More informationNEW ZEALAND DATA SHEET. Each pressurised metered-dose aerosol inhaler contains 100 micrograms of salbutamol (as sulfate)
NEW ZEALAND DATA SHEET RESPIGEN TM 1. Product Name Respigen TM 100 micrograms per actuation inhalation aerosol 2. Qualitative and Quantitative Composition Each pressurised metered-dose aerosol inhaler
More informationA COPD medication delivery device option: an overview of the NEOHALER
A COPD medication delivery device option: an overview of the NEOHALER 2017 Sunovion Pharmaceuticals Inc. All rights reserved 9/17 RESP019-17 Indication and Boxed Warning INDICATION ARCAPTA NEOHALER (indacaterol)
More informationSummary of safety concerns Important identified risks
Valley VI.2 Elements for a public summary NL/H/3661/001-002/DC - Ivabradin Medical VI.2.1 Overview of disease epidemiology Ivabradine is a medicine used for two long-term (chronic) heart conditions: to
More informationSwiss Summary of the Risk Management Plan (RMP) for Nucala (Mepolizumab)
Swiss Summary of the Risk Management Plan (RMP) for Nucala (Mepolizumab) RMP Summary: Version 1, March 2017 EU RMP: Version 2, 26.5.2016 The Risk Management Plan (RMP) is a comprehensive document submitted
More informationCOMBIVENT UDV Product Monograph Page 35 of 39
PART III: CONSUMER INFORMATION Pr Combivent UDV Ipratropium Bromide (as Monohydrate) and Salbutamol (as Salbutamol Sulfate) Nebulizer Solution Read this carefully before you start taking COMBIVENT UDV
More informationCombivent Unit Dose Vials
Combivent Unit Dose Vials Composition 1 unit-dose vial (2.5 ml) solution for inhalation contains: Ipratropium bromide corresponding to 0.5 mg ipratropium bromide anhydrous 0.52 mg Salbutamol sulphate corresponding
More informationBetter Living with Obstructive Pulmonary Disease A Patient Guide
Better Living with Obstructive Pulmonary Disease A Patient Guide Second Edition November 2012 Queensland Health a Better Living with Chronic Obstructive Pulmonary Disease A Patient Guide is a joint project
More informationPRODUCT INFORMATION VENTOLIN ROTACAPS
PRODUCT INFORMATION VENTOLIN ROTACAPS APPROVED NAME: Salbutamol sulphate B.P. PHYSICAL AND CHEMICAL CHARACTERISTICS: Salbutamol sulphate is a white or almost white odourless powder. It is soluble in 4
More informationA study conducted in Norway found the combined estimate for panic and generalized anxiety disorder was 1.10 per 1,000 person-years.
VI.2 Elements for a public summary For sake of completeness, with reference to article 11 of the Directive 2001/83, the applicant retains the option to carve out the patented indication in the national
More informationVildagliptin belongs to a group of medicines called oral antidiabetics.
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Vildagliptin belongs to a group of medicines called oral antidiabetics. Vildagliptin is used in a certain form of diabetes (type
More informationVentolin Accuhaler 200 micrograms salbutamol sulfate
Package Leaflet: Information for the User Ventolin Accuhaler 200 micrograms salbutamol sulfate Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET NAME OF MEDICINE OXIS TURBUHALER Eformoterol fumarate dihydrate (6 µg per inhalation) PRESENTATION OXIS TURBUHALER is a multidose, inspiratory flow driven, metered dose, dry powder
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationSummary of the risk management plan (RMP) for Nucala (mepolizumab)
EMA/671186/2015 Summary of the risk management plan (RMP) for Nucala (mepolizumab) This is a summary of the risk management plan (RMP) for Nucala, which details the measures to be taken in order to ensure
More informationSerevent Diskus 50 microgram per metered dose inhalation powder, pre-dispensed
Agency Approval Date: Not applicable as IA Text Date: 27 April 2015 CO-0111149 GSK Logo Package Leaflet: Information for the User Serevent Diskus 50 microgram per metered dose inhalation powder, pre-dispensed
More informationOXIS TURBUHALER 4.5 µg/dose and 9 µg/dose ASTRAZENECA
10-14 OXIS TURBUHALER 4.5 µg/dose and 9 µg/dose ASTRAZENECA formoterol fumarate dihydrate Inhalation powder Composition Each delivered dose (i.e. the dose leaving the mouthpiece) from Oxis Turbuhaler contains
More informationElements for a public summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Glaucoma is an eye disease that can result in damage to the optic nerve and loss of vision (blindness). It is the major cause
More informationSummary of the risk management plan (RMP) for Kengrexal (cangrelor)
EMA/78859/2015 Summary of the risk management plan (RMP) for Kengrexal (cangrelor) This is a summary of the risk management plan (RMP) for Kengrexal, which details the measures to be taken in order to
More informationAnnex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for ipratropium/salbutamol,
More informationSummary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin)
EMA/247834/2014 Summary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin) Overview of disease epidemiology Epilepsy Epilepsy is a long-term condition affecting the brain and is characterised
More informationRisk Management Plan
Management Plan Active substance: VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Hypertension is generally defined as blood pressure higher than 140/90 mmhg. Hypertension may
More informationVENTOLIN EVOHALER. Salbutamol
VENTOLIN EVOHALER CFC FREE Salbutamol QUALITATIVE AND QUANTITATIVE COMPOSITION VENTOLIN EVOHALER is a pressurised metered-dose inhaler which delivers 100 mcg salbutamol (as sulphate) per actuation, into
More information13.2 Elements for a Public Summary
13.2 Elements for a Public Summary 13.2.1 Overview of disease epidemiology The common cold is one of the most prevalent diseases in humans and is the most common condition for which family doctors are
More informationSummary of the risk management plan (RMP) for Pregabalin Mylan (pregabalin)
EMA/285074/2015 Summary of the risk management plan (RMP) for Pregabalin Mylan (pregabalin) This is a summary of the risk management plan (RMP) for Pregabalin Mylan, which details the measures to be taken
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology High blood pressure, also known as hypertension, occurs in a large percentage of the adult population. Primary (essential) hypertension
More informationWhat is the current cost of COPD (Chronic Obstructive Pulmonary Disease) therapies?
What is the current cost of COPD (Chronic Obstructive Pulmonary Disease) therapies? Medicines in the COPD Ellipta portfolio are highlighted in orange on the graph below: Incruse Ellipta (umeclidinium)
More informationInforMing the PAthway of COPD Treatment 1
InforMing the PAthway of COPD Treatment 1 A landmark trial in over 10,000 symptomatic COPD patients who had experienced at least one exacerbation in the last 12 months 1 (fluticasone furoate/umeclidinium/vilanterol)
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Ipratropiumbromide/Salbutamol Sandoz 0,5/2,5 mg per 2,5 ml, verneveloplossing Ipratropium bromide/salbutamol Read all of this leaflet carefully before you start
More informationVENTOLIN. About your Ventolin Respirator Solution. Read all of this leaflet carefully before you use your medicine
Patient Information VENTOLIN About your Ventolin Respirator Solution Read all of this leaflet carefully before you use your medicine This leaflet does not have the complete information about your medicine.
More informationATROVENT Metered Aerosol (CFC-free)
NAME OF THE DRUG ATROVENT Metered Aerosol (CFC-free) Atrovent metered aerosol contains the active ingredient ipratropium bromide. DESCRIPTION Ipratropium bromide is a synthetic quaternary ammonium compound,
More informationPackage leaflet: Information for the user. Seebri Breezhaler 44 micrograms inhalation powder, hard capsules glycopyrronium (as glycopyrronium bromide)
Package leaflet: Information for the user Seebri Breezhaler 44 micrograms inhalation powder, hard capsules glycopyrronium (as glycopyrronium bromide) Read all of this leaflet carefully before you start
More informationSummary of the risk management plan (RMP) for Portrazza (necitumumab)
EMA/33513/2016 Summary of the risk management plan (RMP) for Portrazza (necitumumab) This is a summary of the risk management plan (RMP) for Portrazza, which details the measures to be taken in order to
More informationCOPD. Helen Suen & Lexi Smith
COPD Helen Suen & Lexi Smith What is COPD? Chronic obstructive pulmonary disease: a non reversible, long term lung disease Characterized by progressively limited airflow and an inability to perform full
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi)
Core Safety Profile Active substance: Budesonide Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi) P - RMS: DK/H/PSUR/0041/001 Date of FAR:
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Malaria is caused by mosquito bites whereby the malaria parasites can enter the body and then live in body tissues such as red
More informationPackage leaflet: Information for the user Pulmicort Respules 0.5 mg, Nebuliser Suspension budesonide
Package leaflet: Information for the user Pulmicort Respules 0.5 mg, Nebuliser Suspension budesonide Read all of this leaflet carefully before you start using this medicine because it contains important
More informationNEW ZEALAND CONSUMER MEDICINE INFORMATION. Salbutamol (as sulfate) 100 micrograms per actuation inhalation aerosol
NEW ZEALAND CONSUMER MEDICINE INFORMATION RESPIGEN TM Salbutamol (as sulfate) 100 micrograms per actuation inhalation aerosol Read all of this leaflet carefully before you start using this medicine. Keep
More informationChronic Obstructive Pulmonary Disease
Page 1 of 5 Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease (COPD) is an 'umbrella' term for people with chronic bronchitis, emphysema, or both. With COPD the airflow to the
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Date: May 02, 2005
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Date: May 02, 2005 SPCBerodualRespimat 1 1. NAME OF THE MEDICINAL PRODUCT Berodual Respimat 20/50 microgram/dose, solution for inhalation 2. QUALITATIVE AND QUANTITATIVE
More informationTIOVA Inhaler (Tiotropium bromide)
Published on: 18 Sep 2014 TIOVA Inhaler (Tiotropium bromide) Composition TIOVA Inhaler Each actuation delivers: Tiotropium Bromide Monohydrate IP equivalent to Tiotropium... 9 mcg Suspended in propellant
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Telmisartan/hydrochlorothiazide is a combination of an angiotensin II receptor antagonist and a thiazide diuretic used in the
More informationPackage leaflet: Information for the user Easyhaler Salbutamol Sulfate 100 and 200 micrograms/dose inhalation powder Salbutamol sulfate (salbutamol)
Package leaflet: Information for the user Easyhaler Salbutamol Sulfate 100 and 200 micrograms/dose inhalation powder Salbutamol sulfate (salbutamol) Read all of this leaflet carefully before you start
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION CORPORATION DATE: 17-04-2015, VERSION 2 VI.2 Elements for
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1. PRODUCT NAME Ventolin Inhaler (CFC-Free) 100 micrograms 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ventolin Inhaler (CFC-Free) is a pressurised metered-dose inhaler which delivers
More informationVentolin Injection 500 micrograms/ml salbutamol sulfate
Package leaflet: Information for the user Ventolin Injection 500 micrograms/ml salbutamol sulfate Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Symbicort Turbohaler 400/12, inhalation powder budesonide, formoterol fumarate dihydrate
PACKAGE LEAFLET: INFORMATION FOR THE USER Symbicort Turbohaler 400/12, inhalation powder budesonide, formoterol fumarate dihydrate Read all of this leaflet carefully before you start taking this medicine.
More informationDo not use Easyhaler Salbutamol if you are allergic (hypersensitive) to: Salbutamol lactose
Package leaflet: Information for the patient user Easyhaler Salbutamol Sulphate 100 and 200 micrograms/dose inhalation powder Salbutamol sulphate (salbutamol) Read all of this leaflet carefully before
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr ANORO ELLIPTA umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation This leaflet is part III of a three-part "Product Monograph" published
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr ANORO ELLIPTA umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation This leaflet is part III of a three-part "Product Monograph" published
More informationAtrovent Administration
Atrovent Administration ICEMA Training 2007 Sherri Shimshy RN OBJECTIVES Describe the pharmacology of Atrovent Identify the indications for use of Atrovent in the Adult Population Identify the indications
More informationPRODUCT INFORMATION VENTOLIN. SUGAR FREE SYRUP and INJECTION. 1-(4-hydroxy-3-hydroxymethylphenyl)-2-(t-butylamino)ethanol Sulphate.
PRODUCT INFORMATION VENTOLIN SUGAR FREE SYRUP and INJECTION NAME OF THE MEDICINE: Salbutamol Sulphate BP Chemical Name 1-(4-hydroxy-3-hydroxymethylphenyl)-2-(t-butylamino)ethanol Sulphate. Structure HOH
More information